Friday, January 25, 2013

IIR’s Immunogenicity Event features exclusive case studies including Amgen, Medimmune, Merck Serono and more!

IIR’s 14th Annual Immunogenicity for Biotherapeutics features 10 case studies aimed at the greatest challenges you face every day in developing safer biologics across the preclinical and clinical spectrum. Hear from Amgen, Medimmune, Merck Serono, Bristol-Meyers Squibb, Teva and more on the following:
  • • Ideal formats for identifying and quantifying NAb response
  • • Improvement of drug tolerance in ADA assays transitioning between phases of drug development
  • • Broadening the types and useful applications of humanized mouse models
  • • Worldwide experience of immunogenicity assessment of biosimilars
  • • Clinical use of nanoparticles to avoid immunogenicity
  • • Evaluating immunogenicity of multi-domain vs. typical biotherapeutics
  • • Optimization of the performance of monoclonal antibodies in-vivo

For more information on the entire Immunogenicity program, download the brochure.

The Immunogenicity for Biotherapeutics Conference is taking place March 18-20, 2013, in Baltimore, MD. Reader of this blog, you receive an exclusive discount of 15% off the standard rate when you register using code XP1838BLOG. If you have any questions about the agenda, feel free to contact Jennifer Pereira.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment